Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice

Antiviral Research

Volumn 94, Issue 1, 2012, Pages 103-110

  Tarbet, E Bart ^a   Maekawa, Masako ^b   Furuta, Yousuke ^b   Babu, Y S ^c   Morrey, John D ^a   Smee, Donald F ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Antiviral; Drug combination; Favipiravir; Peramivir; T 705

Indexed keywords

FAVIPIRAVIR; PERAMIVIR; PLACEBO;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; LIFESPAN; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG WEIGHT; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CALIFORNIA; CYCLOPENTANES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PANDEMICS; PYRAZINES;

MUS; ORTHOMYXOVIRIDAE;

EID: 84859053626     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.03.001     Document Type: Article

References (49)

1. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellog D.L., Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 2001, 45:1162-1167.
2. Bantia S., Arnold C.S., Parker C.D., Upshaw R., Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006, 69:39-45.
3. Bantia S., Kellogg D., Parker C.D., Babu Y.S. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res. 2010, 88:276-280.
4. Bantia S., Kellogg D., Parker C., Upshaw R., Ilyushina N.A., Babu Y.S. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice. Antiviral Res. 2011, 90:17-21.
5. Barroso L., Treanor J., Gubareva L., Hayden F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antiviral Ther. 2005, 10:901-910.
6. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., Zaki S.R., Hayden F.G., Hui D.S., Kettner J.D., Kumar A., Lim M., Shindo N., Penn C., Nicholson K.G. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 2009, 362:1708-1719.
7. Besselaar T.G., Naidoo D., Buys A., Gregory V., McAnerney J., Manamela J.M., Blumberg L., Schoub B.D. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 2008, 14:1809-1810.
8. Boltz D.A., Ilyushina N.A., Arnold C.S., Babu Y.S., Webster R.G., Govorkova E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008, 80:150-157.
9. Update: drug susceptibility of swine origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly Rep. 2009, 58:433-435. Centers for Disease Control and Prevention (CDC).
10. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb. Mortal. Wkly Rep. 2009, 58:467-470. Centers for Disease Control and Prevention (CDC).
11. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193:1626-1629.
12. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St. George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301:1034-1041. Oseltamivir-Resistance Working Group.
13. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
14. Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2011, 60:1-24.
15. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 2002, 46:977-981.
16. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49:981-986.
17. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., Sessions W.M., Xu X., Skepner E., Deyde V., Okomo-Adhiambo M., Gubareva L., Barnes J., Smith C.B., Emery S.L., Hillman M.J., Rivailler P., Smagala J., de Graaf M., Burke D.F., Fouchier R.A., Pappas C., Alpuche-Aranda C.M., López-Gatell H., Olivera H., López I., Myers C.A., Faix D., Blair P.J., Yu C., Keene K.M., Dotson P.D., Boxrud D., Sambol A.R., Abid S.H., St George K., Bannerman T., Moore A.L., Stringer D.J., Blevins P., Demmler-Harrison G.J., Ginsberg M., Kriner P., Waterman S., Smole S., Guevara H.F., Belongia E.A., Clark P.A., Beatrice S.T., Donis R., Katz J., Finelli L., Bridges C.B., Shaw M., Jernigan D.B., Uyeki T.M., Smith D.J., Klimov A.I., Cox N.J. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
18. Govorkova E.A., Webster R.G. Combination chemotherapy for influenza. Viruses 2010, 2:1510-1529.
19. Hall R.J., Peacey M.P., Ralston J.C., Bocacao J., Ziki M., Gunn W., Quirk A., Huang Q.S. Pandemic influenza A(H1N1) viruses currently circulating in New Zealand are sensitive to oseltamivir. Euro. Surveill. 2009, 14:19282.
20. Hata M., Tsuzuki M., Goto Y., Kumagai N., Harada M., Hashimoto M., Tanaka S., Sakae K., Kimura T., Minagawa H., Miyazaki Y. High frequency of amantadine-resistant influenza A (H3N2) viruses in the 2005-2006 season and rapid detection of amantadine-resistant influenza A (H3N2) viruses by MAMA-PCR. Jpn. J. Infect. Dis. 2007, 60:202-204.
21. Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70:121-131.
22. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
23. Ilyushina N.A., Khalenkov A.M., Seiler J.P., Forrest H.L., Bovin N.V., Marjuki H., Barman S., Webster R.G., Webby R.J. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 2010, 84:8607-8616.
24. Ison M.G., Mishin V.P., Braciale T.J., Hayden F.G., Gubareva L.V. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 2006, 193:765-772.
25. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y., Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Takahashi K., Warshauer D., Shult P.A., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
26. Kiso M., Takahashi K., Sakai-Tagawa Y., Shinya K., Sakabe S., Le Q.M., Ozawa M., Furuta Y., Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. USA 2010, 107:882-887.
27. McAuley J.L., Chipuk J.E., Boyd K.L., Van De Velde N., Green D.R., McCullers J.A. PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology. PLoS Pathog. 2010, 6:e1001014.
28. Meijer A., Lackenby A., Hungnes O., Lina B., van der Werf S., Schweiger B., Opp M., Paget J., van de Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560. European Influenza Surveillance Scheme.
29. Moseley C.E., Webster R.G., Aldridge J.R. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir. Viruses 2010, 4:307-311.
30. Mossad S.B. The resurgence of swine-origin influenza A (H1N1). Cleve. Clin. J. Med. 2009, 76:337-343.
31. Oxford J.S., Logan I.S., Potter C.W. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970, 226:82-83.
32. Prichard M.N., Shipman C. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14:181-205.
33. Puzelli S., Facchini M., Di Martino A., Fabiani C., Lackenby A., Zambon M., Donatelli I. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic. Antiviral Res. 2011, 90:205-212.
34. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-498.
35. Rungrotmongkol T., Intharathep P., Malaisree M., Nunthaboot N., Kaiyawet N., Sompornpisut P., Payungporn S., Poovorawan Y., Hannongbua S. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem. Biophys. Res. Commun. 2009, 385:390-394.
36. Shrestha S.S., Swerdlow D.L., Borse R.H., Prabhu V.S., Finelli L., Atkins C.Y., Owusu-Edusei K., Bell B., Mead P.S., Biggerstaff M., Brammer L., Davidson H., Jernigan D., Jhung M.A., Kamimoto L.A., Merlin T.L., Nowell M., Redd S.C., Reed C., Schuchat A., Meltzer M.I. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis. 2011, 52(Suppl. 1):S75-S82.
37. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., Babu Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob. Agents Chemother. 2001, 45:749-757.
38. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wong M.H., Morrey J.D., Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 2007, 51:845-851.
39. Sleeman K., Mishin V.P., Deyde V.M., Furuta Y., Klimov A.I., Gubareva L.V. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 2010, 54:2517-2524.
40. Smee D.F., Huffman J.H., Morrison A.C., Barnard D.L., Sidwell R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 2001, 45:743-748.
41. Smee D.F., Bailey K.W., Morrison A.C., Sidwell R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48:88-93.
42. Smee D.F., Wong M.H., Bailey K.W., Sidwell R.W. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antiviral Chem. Chemother. 2006, 17:185-192.
43. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Morrey J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 2009, 53:2120-2128.
44. Smee D.F., Hurst B.L., Wong M.H., Bailey K.W., Tarbet E.B., Morrey J.D., Furuta Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 2010, 54:126-133.
45. Smee D.F., Hurst B.L., Wong M.-H., Tarbet E.B., Babu Y.S., Klumpp K., Morrey J.D. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010, 88:38-44.
46. Xue Y., Kristiansen I.S., de Blasio B.F. Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave. BMC Public Health 2010, 10:724.
47. Yen H.L., Webster R.G. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunol. 2009, 333:3-24.
48. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., Dziuba N., Holbrook M.R., Zhang L., Kilpatrick J.M., Arnold C.S., Paessler S. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008, 374:198-209.
49. Zaraket H., Saito R., Wakim R., Tabet C., Medlej F., Reda M., Baranovich T., Suzuki Y., Dapat C., Caperig-Dapat I., Dbaibo G.S., Suzuki H. Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season. J. Med. Virol. 2010, 82(7):1224-1228.